arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CV Sciences, Inc.

CVSI
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

CV Sciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth -12.2% ↘
Op. Margin -3.4% ↗
ROIC -15.2% ↗
FCF / Share $-0.00 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity 1.12
info Valuation on last close.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.79M
↓ -12.2% —
Net Income Profit after all expenses
$-958.00K
↑ +60.0% —
Operating Margin Operating profit as % of sales
-3.4%
↑ +75.6% 22th
FCF / Share Free cash flow per share
$-0.00
↑ +44.1% —
Long-Term Debt Long-term obligations
$1.65M
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
20
Returns ↓
13
Financial Health ↑
20
Cash Quality ↑
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 65 quarters